Computer vision and artificial intelligence provide unprecedented opportunities to realize new image-based biomarkers with the potential to drive precision drug development and personalized medicine; particularly in degenerative disease of eye and brain, where tissue sampling is not possible and where no treatments exists. This research project will deploy AI models for multiple tasks including segmentation, classification, anomaly identification and disease progression estimates taken from ophthalmic data collections across multiple clinics.
Age Related Macular Degeneration is the leading cause of irreversible blindness in Canada and the industrialized world, yet there are no treatments for most patients. Tracery Ophthalmics has developed an imaging method, “AMD Imaging” (AMDI) that has generated unprecedented pictures of the retina (film of the eye) that include both known and unknown “flavours” of disease (phenotype). These complex images will be compared against an individual’s genetic makeup (their genotype) and their concurrent illnesses, medications, and lifestyle history (their epigenetics).
This project allows a PDF to take on a feature engineer role in which she will work closely with a biomedical engineer to identify novel features based on Tracerys proprietary imaging method for Age-related Macular Degeneration (AMD). The PDF will serve as a vital link between clinical disease and computing, interacting with both academic and industry partners for automated feature extraction and ultimately machine learning and artificial intelligence.
Join a thriving innovation ecosystem. Subscribe now